Bevacizumab (Avastin), an anti-VEGF monoclonal antibody, inhibits the VEGF signaling pathway, which is pivotal in promoting tumor growth and metastasis through angiogenesis [37]. This evidence concerns the gene VEGFA and neoplasm.